This article is part of the supplement: Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008
Email this article to a friend
Molecular target therapy – towards curative regimen: a 20-year experience in the treatment of acute promyelocytic leukemia (APL) in the Shanghai Institute of Hematology
-
Correspondence: Zhi-Xiang Shen drshenzx@yahoo.com
Journal of Hematology & Oncology 2009, 2(Suppl 1):A1 doi:10.1186/1756-8722-2-S1-A1